Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model

Abstract Alzheimer’s disease (AD) is characterized by amyloidosis, neuroinflammation, cholinergic dysfunction and cognitive impairment. In AD, the cholinergic neuronal marker choline acetyltransferase (ChAT) is reduced and the primate-specific nuclear isoform, 82-kDa ChAT, is mislocalized to cytopla...

Full description

Saved in:
Bibliographic Details
Main Authors: Hadir E. AlQot, Rebecca Jane Rylett
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-024-78751-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846165188285300736
author Hadir E. AlQot
Rebecca Jane Rylett
author_facet Hadir E. AlQot
Rebecca Jane Rylett
author_sort Hadir E. AlQot
collection DOAJ
description Abstract Alzheimer’s disease (AD) is characterized by amyloidosis, neuroinflammation, cholinergic dysfunction and cognitive impairment. In AD, the cholinergic neuronal marker choline acetyltransferase (ChAT) is reduced and the primate-specific nuclear isoform, 82-kDa ChAT, is mislocalized to cytoplasm. Cell-based studies suggest a role for 82-kDa ChAT in regulating expression of AD-related genes with potential reductions in β-amyloid (Aβ) levels. To study this further, we crossed transgenic mice expressing human 82-kDa ChAT with the AD mouse model APPNL-G-F and used molecular techniques and neurobehavioral tests to study the impact of 82-kDa ChAT on AD pathology. These mice had altered expression of genes linked to Aβ clearance and inflammation, and reduced cognitive decline, amyloidosis and gliosis. These effects were inversely related to age and Aβ plaque load and correlated best with 82-kDa ChAT localized to nuclei of neurons. The study suggests a role for 82-kDa ChAT in decreasing AD-like pathology.
format Article
id doaj-art-6a1c4460b13e454b83e19b5852d0dedd
institution Kabale University
issn 2045-2322
language English
publishDate 2024-11-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-6a1c4460b13e454b83e19b5852d0dedd2024-11-17T12:29:43ZengNature PortfolioScientific Reports2045-23222024-11-0114111710.1038/s41598-024-78751-2Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse modelHadir E. AlQot0Rebecca Jane Rylett1Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Robarts Research Institute, University of Western OntarioDepartment of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Robarts Research Institute, University of Western OntarioAbstract Alzheimer’s disease (AD) is characterized by amyloidosis, neuroinflammation, cholinergic dysfunction and cognitive impairment. In AD, the cholinergic neuronal marker choline acetyltransferase (ChAT) is reduced and the primate-specific nuclear isoform, 82-kDa ChAT, is mislocalized to cytoplasm. Cell-based studies suggest a role for 82-kDa ChAT in regulating expression of AD-related genes with potential reductions in β-amyloid (Aβ) levels. To study this further, we crossed transgenic mice expressing human 82-kDa ChAT with the AD mouse model APPNL-G-F and used molecular techniques and neurobehavioral tests to study the impact of 82-kDa ChAT on AD pathology. These mice had altered expression of genes linked to Aβ clearance and inflammation, and reduced cognitive decline, amyloidosis and gliosis. These effects were inversely related to age and Aβ plaque load and correlated best with 82-kDa ChAT localized to nuclei of neurons. The study suggests a role for 82-kDa ChAT in decreasing AD-like pathology.https://doi.org/10.1038/s41598-024-78751-282-kDa choline acetyltransferaseAPPNL-G-F miceAlzheimer’s diseaseβ-Amyloid clearanceMicrogliaNeurobehavioral testing
spellingShingle Hadir E. AlQot
Rebecca Jane Rylett
Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model
Scientific Reports
82-kDa choline acetyltransferase
APPNL-G-F mice
Alzheimer’s disease
β-Amyloid clearance
Microglia
Neurobehavioral testing
title Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model
title_full Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model
title_fullStr Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model
title_full_unstemmed Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model
title_short Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer’s disease-like pathology in the APPNL-G-F knock-in mouse model
title_sort primate specific 82 kda choline acetyltransferase attenuates progression of alzheimer s disease like pathology in the appnl g f knock in mouse model
topic 82-kDa choline acetyltransferase
APPNL-G-F mice
Alzheimer’s disease
β-Amyloid clearance
Microglia
Neurobehavioral testing
url https://doi.org/10.1038/s41598-024-78751-2
work_keys_str_mv AT hadirealqot primatespecific82kdacholineacetyltransferaseattenuatesprogressionofalzheimersdiseaselikepathologyintheappnlgfknockinmousemodel
AT rebeccajanerylett primatespecific82kdacholineacetyltransferaseattenuatesprogressionofalzheimersdiseaselikepathologyintheappnlgfknockinmousemodel